2:10 - 2:30 pmSunday, September 7
LK 130
A social journey to patients at the center of clinical research
LK 130
A social journey to patients at the center of clinical research
Community Manager, Eli Lilly & Co.
Developing new drug treatments cost too much and take too long, with results that all too often don’t meet patient needs. The cost, time, focus, communication and inefficiencies in clinical trials are... Read more

Description

Developing new drug treatments cost too much and take too long, with results that all too often don’t meet patient needs. The cost, time, focus, communication and inefficiencies in clinical trials are a big part of the problem. In 2012, Eli Lilly Clinical Open Innovation (@Lilly_COIwww.lilly.coi) began a journey to change clinical research by making open information about clinical trials more valuable to patients and all involved in clinical research - open, in public, and beyond the towered walls of pharma.

Health Information Technology (HIT) is the toolset. Through a set of projects and methods including Open API, Consortium to help patients match to clinical trials, patient input into clinical trial design, user centered design, open tools and prototypes we continue to work to leverage HIT to better enable open, people-focused engagement in clinical research.

That’s all well and good. But it’s not what I’d like to share at Medicine X. If HIT is the toolset, people are the power that makes the tools hum.

I’d like to share how Social Media and people engagement creates the journey, and how being purposely social gives direction, shape and provides accountability and meaning for the work Lilly COI does. I’d like to share:

  • Fears, perceptions and biases that exist – not just of patients about pharma, but of pharma about patients – and how those perceptions can be changed through open, honest social conversations
  • How awesome it is to be the only pharma at patient meetings, and how it seems that’s where all the good stuff happens
  • How SM relationships have changed (and continue to change) the culture of Eli Lilly and Company, focused on clinical trials
  • The legal and regulatory frameworks that exist in pharma around patient engagement, and how those can be rethought, worked through and torn down
  • How much I’ve learned from patients about Social Media, and how humbling it is to be aware of how much I don’t know
  • How things seem to go best when moving to the uncomfortable zone
  • How I’ve come to meet some new friends, and how we roll
  • When I screw up, when I feel I don’t do enough, and what happens then
  • How Social Media led to the first open, non-lawyered up Patients at The Center of Clinical Research Workshop with patients live tweeting from within the walls of pharma. And what one patient noted while going to the bathroom. (Symplur report #PACCR)
  • Some next step thoughts about how Social Media can further change the relationship between clinical trials and those who can benefit from them

Jerry Matczak is the Community Manager for the Lilly Clinical Open Innovation Team, responsible for connecting people to the team’s efforts. He has a BA in English & Philosophy fromAllegheny College and a MS degree in Information Science from the University of Pittsburgh.

His IT experience at Eli Lilly combined with a variety of sales, marketing and technology roles in startup and consulting environments provide a diverse set of experiences that help him join people & technology.  Jerry is equal part translator, sense-maker, community-builder and networker, with a common-sense understanding of technology and people.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search